Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 26755074)

  • 1. Epidermal growth factor receptor targeting and challenges in glioblastoma.
    Thorne AH; Zanca C; Furnari F
    Neuro Oncol; 2016 Jul; 18(7):914-8. PubMed ID: 26755074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in Targeting the Epidermal Growth Factor Receptor Pathway by Synthetic Products and Its Regulation by Epigenetic Modulators As a Therapy for Glioblastoma.
    Nadeem Abbas M; Kausar S; Wang F; Zhao Y; Cui H
    Cells; 2019 Apr; 8(4):. PubMed ID: 31013819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies.
    Roth P; Weller M
    Neuro Oncol; 2014 Oct; 16 Suppl 8(Suppl 8):viii14-9. PubMed ID: 25342600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of EGFR-Met Interactions in the Pathogenesis of Glioblastoma and Resistance to Treatment.
    Guo G; Narayan RN; Horton L; Patel TR; Habib AA
    Curr Cancer Drug Targets; 2017; 17(3):297-302. PubMed ID: 28004613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic targeting of EGFR-activated metabolic pathways in glioblastoma.
    Gao Q; Lei T; Ye F
    Expert Opin Investig Drugs; 2013 Aug; 22(8):1023-40. PubMed ID: 23731170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
    Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L
    Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance.
    Masui K; Tanaka K; Ikegami S; Villa GR; Yang H; Yong WH; Cloughesy TF; Yamagata K; Arai N; Cavenee WK; Mischel PS
    Proc Natl Acad Sci U S A; 2015 Jul; 112(30):9406-11. PubMed ID: 26170313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting epidermal growth factor receptor co-dependent signaling pathways in glioblastoma.
    Liu F; Mischel PS
    Wiley Interdiscip Rev Syst Biol Med; 2018 Jan; 10(1):. PubMed ID: 28892308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-181b modulates chemosensitivity of glioblastoma multiforme cells to temozolomide by targeting the epidermal growth factor receptor.
    Chen Y; Li R; Pan M; Shi Z; Yan W; Liu N; You Y; Zhang J; Wang X
    J Neurooncol; 2017 Jul; 133(3):477-485. PubMed ID: 28501897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic targeting of EGFRvIII/PDK1 axis in temozolomide resistant glioblastoma.
    Velpula KK; Guda MR; Sahu K; Tuszynski J; Asuthkar S; Bach SE; Lathia JD; Tsung AJ
    Oncotarget; 2017 May; 8(22):35639-35655. PubMed ID: 28410193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR and EGFRvIII Promote Angiogenesis and Cell Invasion in Glioblastoma: Combination Therapies for an Effective Treatment.
    Keller S; Schmidt MHH
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28629170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma.
    Huang PH; Mukasa A; Bonavia R; Flynn RA; Brewer ZE; Cavenee WK; Furnari FB; White FM
    Proc Natl Acad Sci U S A; 2007 Jul; 104(31):12867-72. PubMed ID: 17646646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFRvIII does not affect radiosensitivity with or without gefitinib treatment in glioblastoma cells.
    Struve N; Riedel M; Schulte A; Rieckmann T; Grob TJ; Gal A; Rothkamm K; Lamszus K; Petersen C; Dikomey E; Kriegs M
    Oncotarget; 2015 Oct; 6(32):33867-77. PubMed ID: 26418954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition.
    Liffers K; Kolbe K; Westphal M; Lamszus K; Schulte A
    Target Oncol; 2016 Feb; 11(1):29-40. PubMed ID: 26032687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor in glioblastoma.
    Zawrocki A; Biernat W
    Folia Neuropathol; 2005; 43(3):123-32. PubMed ID: 16245205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erlotinib: early clinical development in brain cancer.
    Addeo R; Zappavigna S; Parlato C; Caraglia M
    Expert Opin Investig Drugs; 2014 Jul; 23(7):1027-37. PubMed ID: 24836441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in
    Felsberg J; Hentschel B; Kaulich K; Gramatzki D; Zacher A; Malzkorn B; Kamp M; Sabel M; Simon M; Westphal M; Schackert G; Tonn JC; Pietsch T; von Deimling A; Loeffler M; Reifenberger G; Weller M;
    Clin Cancer Res; 2017 Nov; 23(22):6846-6855. PubMed ID: 28855349
    [No Abstract]   [Full Text] [Related]  

  • 18. Emerging targeted therapies for glioma.
    Miller JJ; Wen PY
    Expert Opin Emerg Drugs; 2016 Dec; 21(4):441-452. PubMed ID: 27809598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective coexpression of VEGF receptor 2 in EGFRvIII-positive glioblastoma cells prevents cellular senescence and contributes to their aggressive nature.
    Jones KA; Gilder AS; Lam MS; Du N; Banki MA; Merati A; Pizzo DP; VandenBerg SR; Gonias SL
    Neuro Oncol; 2016 May; 18(5):667-78. PubMed ID: 26420897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner.
    Chakravarti A; Chakladar A; Delaney MA; Latham DE; Loeffler JS
    Cancer Res; 2002 Aug; 62(15):4307-15. PubMed ID: 12154034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.